Following the findings from the Diabetes Control and Complications Trial (DCCT), the Epidemiology of Diabetes Interventions and Complications (EDIC) study was initiated as follow-up to examine the long-term effects of the original DCCT interventions on diabetic complications such as cardiovascular events and advanced retinal and renal disease. Over 90 percent of participants from the DCCT study were followed by the EDIC study. Similar to the DCCT study, glycosylated hemoglobin values, fasting lipid levels, serum creatinine values, and other risk factors for cardiovascular disease were measured at different intervals for participants. Cardiovascular complications were assessed with standardized means and classified by an independent committee. The EDIC study has found that intensive diabetes therapy reduced risk of cardiovascular disease in participants with type 1 diabetes and that the differences in outcomes between the intensive and conventional therapy groups persist after long-term study.

Data from the EDIC study up to June 2022 (the end of EDIC Year 29) are available for request. GWAS data may be requested through dbGaP.

The EDIC study aimed to determine the long-term effects of the original DCCT interventions on diabetic complications such as cardiovascular events and advanced retinal and renal disease.

The primary outcome measure for the EDIC study was the time to the first of any cardiovascular disease event. Similar to the DCCT study, secondary outcome measures included assessment of retinopathy, neuropathy, and nephropathy in participants.

The EDIC study enrolled participants from the DCCT study.

Please refer to the protocol for participant exclusion criteria.

Following the initial findings of the DCCT study, the EDIC study has found that intensive diabetes therapy had long-term beneficial effects on the risk of cardiovascular disease in participants with type 1 diabetes and that the differences in outcomes between the intensive and conventional therapy groups persist after long-term study. The EDIC follow-up is ongoing. As of June 2022, 610 of the 711 participants in the DCCT study intensive group, and 586 of the 730 participants in the DCCT study conventional group continue to be followed in EDIC. This represents 94% and 91% (respectively) of the living cohort members.